PharmAbcine Reports First Patient Dosing with PMC-309 in P-Ia/b Study for Advanced or Metastatic Solid Tumors
Shots:
- The company has dosed the first patient with PMC-309 in the P-Ia/b study for the treatment of advanced or metastatic solid tumors
- In the study, P-Ia evaluates PMC-309 as monotx. and in combination with Keytruda to find MTD and RP2D while P-Ib investigates the safety and tolerability on determination of RP2D for the treatment of patients (n=67) with advanced/metastatic solid tumors across sites in Australia
- PMC-309, IgG1 mAb, targets VISTA in immunosuppressive cells to promote anti-tumor activity through activation of T cells, monocytes and proliferation of M1 macrophages
Ref: PharmAbcine | Image: PharmAbcine
Related News:- PharmAbcine Announced the Preclinical Data of PMC-403 for Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
